United States Triple-Negative Breast Cancer KOL Interview, 2019: Prescribing Habits, Key Marketed Brands, and Late-Phase Pipeline Therapies – ResearchAndMarkets.com


DUBLIN–(BUSINESS WIRE)–The “Triple-Negative Breast Cancer KOL Interview – US” report has been added to ResearchAndMarkets.com’s offering.

A US-based key opinion leader provides insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for triple-negative breast cancer. Diagnostic testing, biomarker disease segmentation, and unmet needs are also discussed.

Key pipeline assets highlighted include:

  • balixafortide
  • keytruda
  • sacituzumab govitecan
  • trastuzumab deruxtecan
  • veliparib

For more information about this report visit https://www.researchandmarkets.com/r/d2kmwv



Source link